Company: PRTA
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001559053-25-000017
Chunk: 80

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 80
---
 vesting commencement date of February 27, 2024, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date, and the remainder vesting in equal monthly installments over the next three years thereafter (subject to continued employment).

(6) This option award has a four-year vesting schedule from a vesting commencement date of September 29, 2021, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date, and the remainder vesting in equal monthly installments over the three years thereafter (subject to continued employment).

| 48 |     | 2025 PROXY STATEMENT |

TABLE OF CONTENTS

#### EXECUTIVE COMPENSATION
The following table shows option exercises by our named executive officers during fiscal year 2024.

| Option Exercises and Stock Vested(1)- Fiscal Year 2024 |

| Name             |     | Number of Shares 
 Acquired on      
 Exercise         
 (#)              |   |     | Value Realized 
 on             
 Exercise       
 ($)(2)         |   |
| Gene G. Kinney   |     |                  | — |     |                | — |
| Tran B. Nguyen   |     |                  | — |     |                | — |
| Brandon S. Smith |     |                  | — |     |                | — |
| Carol D. Karp    |     |                  | — |     |                | — |
| Wagner M. Zago   |     |                  | — |     |                | — |

(1) The Company has granted only stock options to our named executive officers.

(2) The value realized on exercise of stock options as shown in this chart was calculated by subtracting the option exercise price from the market price to obtain the value realized per share, and multiplying the value realized per share by the number of shares subject to the portion of the option exercised. The market price for each transaction was determined as follows: If upon exercising, the named executive officer sold the shares acquired, the market price was determined to be the sale price. If upon exercising, the named executive officer kept the shares acquired, then the market price was determined to be the closing price of the Company’s ordinary shares on the date of the exercise.

| 2025 PROXY STATEMENT |     | 49 |

TABLE OF CONTENTS

#### EXECUTIVE COMPENSATION
| Potential Payments and Benefits upon Termination of